Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Finished Goods (2018 - 2025)

Historic Finished Goods for Protalix BioTherapeutics (PLX) over the last 11 years, with Q3 2025 value amounting to $10.9 million.

  • Protalix BioTherapeutics' Finished Goods rose 144631.73% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 144631.73%. This contributed to the annual value of $5.4 million for FY2024, which is 627.79% down from last year.
  • Protalix BioTherapeutics' Finished Goods amounted to $10.9 million in Q3 2025, which was up 144631.73% from $8.6 million recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Finished Goods peaked at $14.5 million during Q1 2023, and registered a low of $706000.0 during Q3 2024.
  • For the 5-year period, Protalix BioTherapeutics' Finished Goods averaged around $8.5 million, with its median value being $8.3 million (2022).
  • Its Finished Goods has fluctuated over the past 5 years, first crashed by 9146.21% in 2024, then soared by 144631.73% in 2025.
  • Protalix BioTherapeutics' Finished Goods (Quarter) stood at $11.5 million in 2021, then dropped by 7.88% to $10.6 million in 2022, then crashed by 45.24% to $5.8 million in 2023, then dropped by 6.28% to $5.4 million in 2024, then soared by 100.35% to $10.9 million in 2025.
  • Its Finished Goods was $10.9 million in Q3 2025, compared to $8.6 million in Q2 2025 and $7.0 million in Q1 2025.